ULTI.OL - ULTIMOVACS
kr7.12 0.09 (1.28%)
Updated: 08:43 May 10, 2024 ESTNext Session's AI Forecast
68.93%
Avg. Accuracy (AI)
kr9.52
Next Week's AI Forecast
0%
Trend's Accuracy (AI)
kr13.11
| Rank (0-100) |
| Rank (0-100) |
| Curr. Week | Curr. Month | Curr. Quarter | Next Quarter | Curr Year | -0.07 | -1.96 | -0.55 | 0.08 | -0.13 |
|---|
CURRENT VOLATILITY RANK
Variation from the lowest to the highest value in a period.
| Curr. Week | Curr. Month | Curr. Quarter | Next Quarter | Curr Year | 6.78 | 4.49 | 5.45 | 3.77 | 3.38 |
|---|
STOCHASTIC METRIC
The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.
| Curr. Week | Next Week | Curr. Month | Curr. Quarter | 0% | 36.21% | 12.03% | 0.45% |
|---|
MOVING AVERAGE METRIC
| 5 Sessions | Change 5 Sessions | 20 Sessions | Change 20 Sessions | 50 Sessions | Change 50 Sessions | 200 Sessions | 7.36 | 1.38% | 7.26 | -14.49% | 8.49 | -90.37% | 88.12 |
|---|
RSI METRIC
| RS Hour | RSI Hour | RS Day | RSI Day | 0.63 | 74.55 | 0.45 | 38.65 |
|---|
ULTIMOVACS Technical Analysis News
ULTIMOVACS
Ullernchausséen 64
Oslo 0379
Norway
47 41 38 00 80
https://www.ultimovacs.com
| Sectors: | Healthcare |
| Industry: | Biotechnology |
| F. Time Employees: | 24 |
Description
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Corporate Governance
Ultimovacs ASA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.